| payload |
{"created_at":"2026-04-08T02:28:02.401 {"created_at":"2026-04-08T02:28:02.401723+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:6f4c461bd3894ec0","evidence_event_ids":["evt_8dda497b2d90"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1356576/0001104659-26-040497.txt","as_of":"2026-04-08T02:28:02.401723+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1356576/0001104659-26-040497.txt","company":"SUPERNUS PHARMACEUTICALS, INC.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1356576/0001104659-26-040497.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_2f80e264ac9780d9","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1356576/0001104659-26-040497.txt","content_type":"text/plain","enriched_at":"2026-04-08T03:24:37.461743+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1356576/0001104659-26-040497.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1356576/0001104659-26-040497.txt","source_event_id":"evt_8dda497b2d90","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"66bc35118717aee9","kind":"sec_filing","published_at":"20260407","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-01","2026-04-07","2026-04-08","April 21, 2020","May 5, 2025"],"entities":[{"asset_class":"equity","name":"Supernus Pharmaceuticals, Inc.","relevance":"high","symbol":"","type":"issuer_company"},{"asset_class":"equity","name":"Navitor Pharmaceuticals, Inc.","relevance":"high","symbol":"","type":"counterparty"},{"asset_class":"equity","name":"Navitor Pharmaceuticals, LLC","relevance":"high","symbol":"","type":"counterparty"},{"asset_class":"intellectual_property","name":"NV-5138 (SPN-820)","relevance":"high","symbol":"","type":"asset_or_program"}],"event_type":"merger_acquisition","information_gaps":["What changed vs prior known state is not provided in the signal; only that an 8-K was filed is known.","The specific development/regulatory/commercial milestones and their timing/conditions are not enumerated in the provided text.","No financial statement impact, accounting treatment, or immediate cash outlay amounts beyond the stated obligations are provided in the excerpt.","The identities/definition of \u201cRestricted Parties\u201d are not included in the provided text.","The exhibit content (Exhibit 2.1) is referenced but not included, so additional terms are unknown."],"key_facts":["Form 8-K filed by Supernus Pharmaceuticals, Inc. reports an Asset Purchase Agreement entered on April 1, 2026.","The agreement is with Navitor Pharmaceuticals, Inc. and Navitor Pharmaceuticals, LLC (together, the \u201cSellers\u201d).","Supernus agreed to acquire Purchased Assets including intellectual property rights, inventory and manufacturing materials, regulatory and clinical materials, permits, data and records, certain contract rights, and related goodwill, each related to the compound NV-5138 or SPN-820.","The purchase price consists of Supernus\u2019s obligation to (i) effect and complete one (1) Phase 2b Study and (ii) make milestone payments of up to $350 million contingent on specified development, regulatory, and commercial milestones.","After completion of the Phase 2 Study, if Supernus determines in its sole reasonable discretion that the study was not successful, Supernus will have no further obligation to pursue milestone achievement or commercialization of the Compound.","The agreement includes customary representations and warranties and customary indemnification provisions.","The agreement includes a five-year post-closing non-competition and non-solicitation covenant applicable to Restricted Parties.","Exhibit 2.1 is the Asset Purchase Agreement dated April 1, 2026 (filed as an exhibit to the 8-K)."],"numeric_claims":[{"label":"Milestone payments maximum","value":"up to $350 million"},{"label":"Phase study required","value":"1 Phase 2b Study"},{"label":"Non-competition/non-solicitation duration","value":"5 years"}],"primary_claim":"On April 1, 2026, Supernus entered into an Asset Purchase Agreement to acquire Purchased Assets related to NV-5138 (SPN-820) from Navitor Pharmaceuticals, Inc. and Navitor Pharmaceuticals, LLC, with milestone payments up to $350 million contingent on specified achievements.","relevance_score":0.78,"sentiment":"mixed","source_quality":"high","summary":"Supernus Pharmaceuticals, Inc. filed a Form 8-K reporting that it entered into an Asset Purchase Agreement on April 1, 2026 with Navitor entities to acquire assets related to NV-5138 (SPN-820). The purchase price includes funding for a Phase 2b study and milestone payments up to $350 million, contingent on development, regulatory, and commercial milestones.","topics":["8-K","asset purchase agreement","Phase 2b study","milestone payments","intellectual property acquisition","non-competition covenant","indemnification"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 SUPERNUS PHARMACEUTICALS, INC. \u00b7 Filed 20260407","ticker":"SUPN","tickers":["SUPN"],"title":"SUPN filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1356576/0001104659-26-040497.txt"}}... |